Trial
NCT03354637
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Aclaris Therapeutics, Inc.
Collaborators
—
Condition
Alopecia Areata
Intervention
ATI-50002 high dose
Why stopped
The double-blind primary endpoint was not met. Open Label Extension period halted as a result.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-06-05